Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador
NCT ID: NCT01589848
Last Updated: 2013-07-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
81 participants
OBSERVATIONAL
2013-03-31
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
a. There are patients with von Willebrand Disease in Cuenca.
2. Primary question
a. How many women referred with a history of bleeding may have von Willebrand disease?
3. Secondary
1. Associations between the bleeding score and initial laboratory studies
2. What are the differences on subgroups of enrolled patients with the bleeding score?
4. Ancillary
1. What is the clinical and socio-economic status of women with von Willebrand Disease in Cuenca?
2. What is the clinical and socio-economic status of patients with Hemophilia in Cuenca?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Von Willebrand Disease in the Netherlands
NCT03521583
Prevalence, Risk Factors and Outcomes of Pediatric Vascular Thrombosis
NCT05889897
REAL-LIFE DATA OF CONSTITUTIONAL VON WILLEBRAND DISEASE IN WESTERN FRANCE (HOPSCOTcH-WILL)
NCT03875924
Hepatic Artery Stenosis and Thrombosis After Liver Transplantation in Children
NCT05818644
Ultra-low-dose Chest CT for HHT
NCT04874558
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A world survey published that Ecuador, with a population of 14,790,608 people, has 238 patients with hemophilia, 45 people with von Willebrand disease (vWD) and 13 patients with other bleeding disorders including rare factor deficiencies and platelet disorders.
The Ecuadorian census of 2010 indicates that Cuenca district (canton) has 505,585 inhabitants. According to a local reference, Cuenca has no reports of vWD and it has registered 20-40 patients with hemophilia A and B. However Cuenca may host approximately 10,000 people with vWD because it affects both males and females. One plausible explanation for this lag is that the diagnostic suspicions of vWD had not been proven because of the lack of a special coagulation laboratory in Cuenca that would allow professionals to make a positive diagnosis.
This is the first clinical, demographic and socio-economic study of patients registered with hemophilia and of Cuenca women with possible vWD who are referred from dentists and physicians from public and private health centers. The instruments will be validated surveys and screening coagulation studies.
As far as we know Ecuador has not published studies on coagulopathies. Our aim is to initiate a process to eventually reach the goal to offer adequate diagnostic and therapeutic interventions to human victims of these diseases, within a program of service, teaching and research.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
von Willebrand women
Referred women who may have von Willebrand Disease
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects referred from professionals of public and private health services, who have filled the initial hemorrhage survey.
* Must be referred women who sign the informed consent form.
* Patients who answer the standardized bleeding score questionnaire (BS).
* Patients who answer the quality of life questionnaire (SF-12).
* Patients who answer the socio-economic survey.
* Patients who accept to provide a venous blood sample for the initial laboratory tests.
Exclusion Criteria
* Patients taking medicines which may affect the coagulation cascade or the number or function of platelets.
18 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidad del Azuay
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jaime M. Moreno A., M.D., M.S., F.A.C.P.
Jaime M. Moreno A, M.D., M.S., F.A.C.P.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jaime M. Moreno A., M.D., M.S.
Role: PRINCIPAL_INVESTIGATOR
Universidad del Azuay (UAzuay)
Jacinto Guillen G., Eng., M.S.
Role: STUDY_CHAIR
Universidad del Azuay (UAzuay)
Rodrigo Cueva M., Econ., M.S.
Role: STUDY_DIRECTOR
Universidad del Azuay (UAzuay)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UAzuay
Cuenca, Azuay, Ecuador
Universidad del Azuay (UDA)
Cuenca, Azuay, Ecuador
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UAzuay
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.